Ido Amit

This inventor holds 5 USPTO granted patents and 15 published patent applications and 2 EPO patents. Top assignees: Yeda Research and Develpment & Co. Ltd, Yeda Research and Development Co. Ltd. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ido Amit. Retrieved from https://idiyas.com/inventor/ido-amit

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5 (Patent Applications = 15)

% Patents Active = 80.0

EPO Patents = 2 (Patent Applications = 14)

Average Co-Inventor Count = 4.3

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

4 out of 1,168

Yeda Research and Develpment & Co. Ltd

patents

1 out of 29

Yeda Research and Development Co. Ltd

patents

Years Active: 2020-2026

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516313 - METHOD FOR STABILIZING INTRACELLULAR RNA (2026-01-06),

2. 11485971 - CRISP-seq, an integrated method for massively parallel single cell RNA-seq and CRISPR pooled screens (2022-11-01),

3. 11400156 - Methods of preventing secondary infections (2022-08-02),

4. 10610588 - Methods of preventing secondary infections (2020-04-07),

5. 10590467 - Methods and kits for analyzing DNA binding moieties attached to DNA (2020-03-17),

Title: Ido Amit: Innovator in Biomedical Research

Introduction

Ido Amit is a prominent inventor based in Rehovot, Israel. He has made significant contributions to the field of biomedical research, particularly in the areas of single-cell RNA sequencing and methods for preventing secondary infections. With a total of 5 patents to his name, Amit continues to push the boundaries of innovation in his field.

Latest Patents

Among his latest patents are CRISP-seq, an integrated method for massively parallel single-cell RNA-seq, and CRISPR pooled screens. Additionally, he has developed a method for treating or preventing diseases associated with secondary infections. This method involves administering a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen, along with an agent that down-regulates at least one extracellular matrix-associated polypeptide.

Career Highlights

Ido Amit is affiliated with Yeda Research and Development Co. Ltd., where he has been instrumental in advancing research initiatives. His work has garnered attention for its innovative approaches to complex biomedical challenges.

Collaborations

Some of his notable coworkers include Irit Sagi and Dalit Talmi-Frank, who have collaborated with him on various research projects.

Conclusion

Ido Amit's contributions to biomedical research exemplify the spirit of innovation and dedication to improving health outcomes. His patents and collaborative efforts continue to influence the field significantly.

Profile summary based on public USPTO records.